Angiodroid

Angiodroid SpA is an Italian medical technology company based in San Lazzaro di Savena, Bologna. The company specializes in developing and manufacturing advanced medical devices, with a focus on automatic carbon dioxide (CO2) injection systems for angiography. Angiodroid's flagship product is the first and only automatic CO2 injector authorized for use during peripheral angiography procedures. This innovative technology offers a safer, more cost-effective, and less risky alternative to traditional iodine-based contrast media, particularly beneficial for patients with renal insufficiency. The Angiodroid CO2 injector has received over 30 international certifications, including CE marking for the European market. As of February 2023, the company reported a turnover of EUR 3 million for 2022.

Angiodroid's patented automatic CO2 dosing control system enables safer angiograms with fewer side effects while providing imaging quality comparable to standard methods. The technology eliminates the risk of contrast-induced acute kidney injury, which affects approximately 30% of patients undergoing traditional angiography procedures. Angiodroid has expanded its product portfolio to include Angiopulse, an innovative IABP console for passive counterpulsation therapy, designed to improve efficacy and patient stabilization.